References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-193-9-15-26

nogr-1732

Research Article

КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ

CLINICAL GASTROENTEROLOGY

Современные представления о патогенезе, диагностике и лечении хеликобактерной инфекции

Modern knowledge on pathogenesis, diagnosis and treatment of helicobacter infection

https://orcid.org/0000-0003-4249-3053

Киселев

Г. Ю.

Kiselev

H. Yu.

Киселев Герман Юрьевич - студент Международной Школы «Медицина Будущего».

119048, г. Москва, ул. Трубецкая, д. 8/1

Herman Yu. Kiselev - undergraduate student of International School “Medicine of the Future”.

8/1 Trubetskaya St., Moscow, 119048

https://orcid.org/0000-0002-9885-7672

Горленко

К. Л.

Gorlenko

C. L.

Горленко Кирилл Леонидович - студент Международной Школы Медицина Будущего.

119048, г. Москва, ул. Трубецкая, д. 8/1

Cyrill L. Gorlenko - undergraduate student of International School “Medicine of the Future”.

8/1 Trubetskaya St., Moscow, 119048

mr.gorlenko@mail.ru

https://orcid.org/0000-0002-4218-4456

Эль-Тарави

Я. А.

El-Taravi

Ya. A.

Эль-Тарави Ясмин Ахмед Али - студентка Международной Школы «Медицина Будущего».

119048, г. Москва, ул. Трубецкая, д. 8/1

Yasmin A. El- Taravi - undergraduate student of International School “Medicine of the Future”.

8/1 Trubetskaya St., Moscow, 119048

https://orcid.org/0000-0002-2611-9320

Порубаева

Э. Э.

Porubayeva

E. E.

Порубаева Эрика Эдуардовна - студентка Международной Школы «Медицина Будущего».

119048, г. Москва, ул. Трубецкая, д. 8/1

Erika E. Porubayeva, undergraduate student of International School “Medicine of the Future”.

8/1 Trubetskaya St., Moscow, 119048

https://orcid.org/0000-0003-1864-5635

Буданова

Е. В.

Budanova

E. V.

Буданова Елена Вячеславовна – кандидат медицинских наук, доцент кафедры микробиологии, вирусологии и иммунологии ИОЗ им. Ф. Ф. Эрисмана.

119048, г. Москва, ул. Трубецкая, д. 8/1

Elena V. Budanova, MD, PhD, Institute of Public Health, Department of Microbiology, Virology and Immunology.

8/1 Trubetskaya St., Moscow, 119048

ФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation

2021

10122021

091526

2021

Киселев Г.Ю., Горленко К.Л., Эль-Тарави Я.А., Порубаева Э.Э., Буданова Е.В.

Kiselev H.Y., Gorlenko C.L., El-Taravi Y.A., Porubayeva E.E., Budanova E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/1732

Хеликобактерная инфекция - важный фактор риска развития гастрита, язвенной болезни желудка и двенадцатиперстной кишки, онкологических заболеваний желудочно-кишечного тракта, а также некоторых других болезней, например, псориаза. H. pylori был отнесен Агентством по Исследованию Рака (IARC) к канцерогенам первой группы, поэтому совершенствование методов диагностики (особенно малоинвазивных и неинвазивных) и терапии хеликобактерной инфекции важны для снижения риска развития данной патологии и ассоциированных заболеваний. Со времен первого обнаружения данного микроорганизма представления о патогенезе хеликобактерной инфекции сильно расширились: обнаружено множество факторов вирулентности возбудителя (например, адгезины, хемотаксины, уреаза, различные экзотоксины), играющих роль в инвазии, адгезии и цитотоксичности H. pylori. Методы диагностики хеликобактерной инфекции постоянно совершенствуются, продолжается исследование их специфичности, информативности и точности. Однако, несмотря на все перечисленное, в мире до сих пор остро стоит проблема эрадикации H. pylori, в том числе, в силу его растущей антибиотикорезистентности. Целью данного обзора явилась систематизация современных данных о патогенезе, диагностике и лечении хеликобактерной инфекции.

Since its discovery, H. pylori infection is known as one of the risk factor for the development of gastritis, peptic ulcer, GIT tumors and numerous other diseases such as psoriasis. Infection caused by H. pylori is posed as the top oncogene in the risk of the development of gastrocarcinoma (First class oncogene by Classification of International Agency for Research of Cancer). That is why the elaboration of fast and accurate methods of diagnosis (non-invasive methods especially) and proper treatment of Helicobacter infection is still very important. Throughout the time, knowledge about pathogenesis of Helicobacter infection have been expanded with the detection of adhesins, chemotaxins and multiple virulence factors related to invasion, adhesion and cytotoxicity of H. pylori. Invasive and non-invasive methods of diagnostics are currently being improved in effectiveness and accuracy. But still, due to different factors (e. g., dramatically increasing drug resistance), eradication of H. pylori remains big problem world-wide. Our review represents modern data on pathogenesis, diagnostics and treatment of Helicobacter infection.

Хеликобактерная инфекцияH. pyloriгастритязвенная болезнь желудкатерапия хеликобактерной

Helicobacter infectionH. pylorigastritispeptic ulcerHelicobacter infection treatment

References1

Marshall B.J., Warren J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):1311-5. doi: 10.1016/S0140-6736(84)91816-6. PMID: 6145023

Marshall B. J. The campylobacter pylori story. Scand J Gastroenterol Suppl. 1988;146:58-66. doi: 10.3109/00365528809099131.PMID: 3067335

Leontiadis G.I., Moayyedi P., Ford A. C. Helicobacter pylori infection. BMJ Clin Evid. 2009 Oct 1;2009:0406. PMID: 21718575.

Pohl D., Keller P. M., Bordier V., Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol. 2019 Aug 28;25(32):4629-4660. doi: 10.3748/wjg.v25.i32.4629. PMID: 31528091.

Sutton P., Boag J. M. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2019 Nov 28;37(50):7295-7299. doi: 10.1016/j.vaccine.2018.01.001. PMID: 29627231.

Nawacki Ł., Czyż A., Bryk P., et al. Can urea breath test (UBT) replace rapid urea test (RUT)? Pol Przegl Chir. 2018 Jun 4;90(5):44-48. doi: 10.5604/01.3001.0012.0669. PMID: 30426947.

Kalali B., Mejías-Luque R., Javaheri A., Gerhard M. H. pylori virulence factors: influence on immune system and pathology. Mediators Inflamm. 2014;2014:426309. doi: 10.1155/2014/426309. PMID: 24587595.

Kable M.E., Hansen L. M., Styer C. M., et al. Host Determinants of Expression of the Helicobacter pylori BabA Adhesin. Sci Rep. 2017 Apr 18;7:46499. doi: 10.1038/srep46499. PMID: 28418004.

Björnham O., Bugaytsova J., Borén T., Schedin S. Dynamic force spectroscopy of the Helicobacter pylori BabA-Lewis b binding. Biophys Chem. 2009 Jul;143(1-2):102-5. doi: 10.1016/j.bpc.2009.03.007. PMID: 19344994.

Aspholm-Hurtig M., Dailide G., Lahmann M., et al. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science. 2004 Jul 23;305(5683):519-22. doi: 10.1126/science.1098801. PMID: 15273394.

Mahdavi J., Sondén B., Hurtig M., et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science. 2002 Jul 26;297(5581):573-8. doi: 10.1126/science.1069076. PMID: 12142529.

Gu H. Role of Flagella in the Pathogenesis of Helicobacter pylori. Curr Microbiol. 2017 Jul;74(7):863-869. doi: 10.1007/s00284-017-1256-4. PMID: 28444418.

De Brito B. B., Da Silva F. A.F., Soares A. S., et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019 Oct 7;25(37):5578-5589. doi: 10.3748/wjg.v25.i37.5578. PMID: 31602159.

Clyne M., Ocroinin T., Suerbaum S., et al. Adherence of isogenic flagellum-negative mutants of Helicobacter pylori and Helicobacter mustelae to human and ferret gastric epithelial cells. Infect Immun. 2000 Jul;68(7):4335-9. doi: 10.1128/IAI.68.7.4335-4339.2000. PMID: 10858255.

Worku M.L., Karim Q. N., Spencer J., Sidebotham R. L. Chemotactic response of Helicobacter pylori to human plasma and bile. J Med Microbiol. 2004 Aug;53(Pt 8):807-811. doi: 10.1099/jmm.0.45636-0. PMID: 15272070.

Bollmann R., Seeburg A., Parschau J., et al. Genotypic and phenotypic determination of five virulence markers in clinical isolates of Escherichia coli. FEMS Immunol Med Microbiol. 1997 Apr;17(4):263-71. doi: 10.1111/j.1574-695X.1997.tb01020.x. PMID: 9143884.

Wu J., Okamura D., Li M., et al. An alternative pluripotent state confers interspecies chimaeric competency. Nature. 2015 May 21;521(7552):316-21. doi: 10.1038/nature14413. Epub 2015 May 6. PMID: 25945737.

Chauhan N., Tay A. C.Y., Marshall B. J., Jain U. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: An overview. Helicobacter. 2019 Feb;24(1): e12544. doi: 10.1111/hel.12544. PMID: 30324717.

Atherton J.C., Peek R. M. Jr, Tham K. T., Cover T. L., Blaser M. J. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 1997 Jan;112(1):92-9. doi: 10.1016/s0016-5085(97)70223-3. PMID: 8978347.

Kern B., Jain U., Utsch C., et al. Characterization of Helicobacter pylori VacA-containing vacuoles (VCVs), VacA intracellular trafficking and interference with calcium signalling in T lymphocytes. Cell Microbiol. 2015 Dec;17(12):1811-32. doi: 10.1111/cmi.12474. PMID: 26078003.

Caston R.R., Sierra J. C., Foegeding N. J., et al. Functional Properties of Helicobacter pylori VacA Toxin m1 and m2 Variants. Infect Immun. 2020 May 20;88(6): e00032-20. doi: 10.1128/IAI.00032-20. PMID: 32284370.

Kim J.M., Kim J. S., Yoo D. Y., et al. Stimulation of dendritic cells with Helicobacter pylori vacuolating cytotoxin negatively regulates their maturation via the restoration of E2F1. Clin Exp Immunol. 2011 Oct;166(1):34-45. doi: 10.1111/j.1365-2249.2011.04447.x. PMID: 21910723.

Lu H., Hsu P. I., Graham D. Y., Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology. 2005 Apr;128(4):833-48. doi: 10.1053/j.gastro.2005.01.009. PMID: 15825067.

Farzi N., Yadegar A., Aghdaei H. A., Yamaoka Y., Zali M. R. Genetic diversity and functional analysis of oipA gene in association with other virulence factors among Helicobacter pylori isolates from Iranian patients with different gastric diseases. Infect Genet Evol. 2018 Jun;60:26-34. doi: 10.1016/j.meegid.2018.02.017. PMID: 29452293.

Miftahussurur M., Yamaoka Y., Graham D. Y. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017 Mar 21;19: e4. doi: 10.1017/erm.2017.4. PMID: 28322182.

Franco A.T., Johnston E., Krishna U., et al. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res. 2008 Jan 15;68(2):379-87. doi: 10.1158/0008-5472.CAN-07-0824. PMID: 18199531.

Kanada R., Uchida T., Tsukamoto Y., et al. Genotyping of the cagA gene of Helicobacter pylori on immunohistochemistry with East Asian CagA-specific antibody. Pathol Int. 2008 Apr;58(4):218-25. doi: 10.1111/j.1440-1827.2008.02214.x. PMID: 18324914.

Selbach M., Moese S., Hauck C. R., Meyer T. F., Backert S. Src is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo. J Biol Chem. 2002 Mar 1;277(9):6775-8. doi: 10.1074/jbc.C100754200. PMID: 11788577.

Ren S., Higashi H., Lu H., Azuma T., Hatakeyama M. Structural basis and functional consequence of Helicobacter pylori CagA multimerization in cells. J Biol Chem. 2006 Oct 27;281(43):32344-52. doi: 10.1074/jbc.M606172200. PMID: 16954210.

Yamaoka Y., Osato M. S., Sepulveda A. R., et al. Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect. 2000 Feb;124(1):91-6. doi: 10.1017/s0950268899003209. PMID: 10722135.

Nishikawa H., Hatakeyama M. Sequence Polymorphism and Intrinsic Structural Disorder as Related to Pathobiological Performance of the Helicobacter pylori CagA Oncoprotein. Toxins (Basel). 2017 Apr 13;9(4):136. doi: 10.3390/toxins9040136. PMID: 28406453.

Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004 Sep;4(9):688-94. doi: 10.1038/nrc1433. PMID: 15343275.

Hatakeyama M. Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA. Oncogene. 2008 Nov 24;27(55):7047-54. doi: 10.1038/onc.2008.353. PMID: 19029944.

Shibayama K., Wachino J., Arakawa Y., et al. Metabolism of glutamine and glutathione via gamma-glutamyltranspeptidase and glutamate transport in Helicobacter pylori: possible significance in the pathophysiology of the organism. Mol Microbiol. 2007 Apr;64(2):396-406. doi: 10.1111/j.1365-2958.2007.05661.x. PMID: 17381553.

Kim K.M., Lee S. G., Kim J. M., et al. Helicobacter pylori gamma-glutamyltranspeptidase induces cell cycle arrest at the G1-S phase transition. J Microbiol. 2010 Jun;48(3):372-7. doi: 10.1007/s12275-010-9293-8. PMID: 20571956.

Schmees C., Prinz C., Treptau T., et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology. 2007 May;132(5):1820-33. doi: 10.1053/j.gastro.2007.02.031. PMID: 17484877.

Oertli M., Noben M., Engler D. B., et al. Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3047-52. doi: 10.1073/pnas.1211248110. PMID: 23382221.

Gong M., Ling S. S., Lui S. Y., Yeoh K. G., Ho B. Helicobacter pylori gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. Gastroenterology. 2010 Aug;139(2):564-73. doi: 10.1053/j.gastro.2010.03.050. PMID: 20347814.

Takeshita H., Watanabe E., Norose Y., Ito Y., Takahashi H. Neutralizing antibodies for Helicobacter pylori urease inhibit bacterial colonization in the murine stomach in vivo. Biomed Res. 2019;40(2):87-95. doi: 10.2220/biomedres.40.87. PMID: 30982804.

Fouladi M., Sarhadi S., Tohidkia M., et al. Selection of a fully human single domain antibody specific to Helicobacter pylori urease. Appl Microbiol Biotechnol. 2019 Apr;103(8):3407-3420. doi: 10.1007/s00253-019-09674-6. PMID: 30810777.

Nim Y.S., Wong K. B. The maturation pathway of nickel urease. Inorganics. 2019;7(7). doi: 10.3390/inorganics7070085.

Pagoni A., Daliani T., Macegoniuk K., Vassiliou S., Berlicki Ł. Catechol-based inhibitors of bacterial urease. Bioorg Med Chem Lett. 2019 May 1;29(9):1085-1089. doi: 10.1016/j.bmcl.2019.02.032. PMID: 30850166.

Rain J.C., Selig L., De Reuse H., et al. The protein-protein interaction map of Helicobacter pylori. Nature. 2001 Jan 11;409(6817):211-5. doi: 10.1038/35051615. PMID: 11196647.

Yuen M.H., Fong Y. H., Nim Y. S., Lau P. H., Wong K. B. Structural insights into how GTP-dependent conformational changes in a metallochaperone UreG facilitate urease maturation. Proc Natl Acad Sci USA. 2017 Dec 19;114(51): E10890-E10898. doi: 10.1073/pnas.1712658114. PMID: 29203664.

Weeks D.L., Eskandari S., Scott D. R., Sachs G. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science. 2000 Jan 21;287(5452):482-5. doi: 10.1126/science.287.5452.482. PMID: 10642549.

Bury-Moné S., Skouloubris S., Labigne A., De Reuse H. The Helicobacter pylori Urel protein: Role in adaptation to acidity and identification of residues essential for its activity and for acid activation. Mol. Microbiol. 2001; 42(4):1021-1034. doi: 10.1046/j.1365-2958.2001.02689.x.

Makristathis A., Hirschl A. M., Mégraud F., Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter. 2019 Sep; 24 (Suppl 1): e12641. doi: 10.1111/hel.12641. PMID: 31486244.

Kawano K., Yazumi S., Kawano R., Nishi K. Detection Capability of the Stool Helicobacter pylori Antigen Kit Using Gastric Juice Collected during Esophagogastroduodenoscopy. Chin Med J (Engl). 2018 Sep 20;131(18):2252-2253. doi: 10.4103/0366-6999.240818. PMID: 30203808.

Sabbagh P., Mohammadnia-Afrouzi M., Javanian M., et al. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):55-66. doi: 10.1007/s10096-018-3414-4. PMID: 30414090.

Lopes A.I., Vale F. F., Oleastro M. Helicobacter pylori infection - recent developments in diagnosis. World J Gastroenterol. 2014 Jul 28;20(28):9299-313. doi: 10.3748/wjg.v20.i28.9299. PMID: 25071324.

Dahlén G., Hassan H., Blomqvist S., Carlén A. Rapid urease test (RUT) for evaluation of urease activity in oral bacteria in vitro and in supragingival dental plaque ex vivo. BMC Oral Health. 2018 May 18;18(1):89. doi: 10.1186/s12903-018-0541-3. PMID: 29776416.

Aumpan N., Vilaichone R. K., Chotivitayatarakorn P., et al. High Efficacy of Rapid Urine Test for Diagnosis of Helicobacter pylori Infection in Thai People. Asian Pac J Cancer Prev. 2019 May 25;20(5):1525-1529. doi: 10.31557/APJCP.2019.20.5.1525. PMID: 31128058.

Son J.H., Lebwohl B., Sepulveda A. R., Lagana S. M. Utilization Rate of Helicobacter pylori Immunohistochemistry Is Not Associated With the Diagnostic Rate of Helicobacter pylori Infection. Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):694-698. doi: 10.1097/PAI.0000000000000680. PMID: 30499817.

Бордин Д. С., Войнован И. Н., Колбасников С. В., Эмбутниекс Ю. В. Методы диагностики инфекции helicobacter pylori в клинический практике. Терапевтический архив. 2018. 90(12):133-139.

Bordin D.S., Voynovan I. N., Kolbasnikov S. V., Embutnieks Y. V. Diagnosis of Helicobacter pylori infection in clinical practice. Terapevticheskii arkhiv. 2018; 90(12): 133-139. doi: 10.26442/00403660.2018.12.000020

Bachir M., Allem R., Benejat L., et al. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. J Antimicrob Chemother. 2018 Aug 1;73(8):2034-2038. doi: 10.1093/jac/dky167. PMID: 29762682.

Contreras M., Benejat L., Mujica H., et al. Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts. J Med Microbiol. 2019 Sep;68(9):1287-1291. doi: 10.1099/jmm.0.001051. PMID: 31364966.

Best L.M., Takwoingi Y., Siddique S., et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018 Mar 15;3(3): CD012080. doi: 10.1002/14651858.CD012080.pub2. PMID: 29543326.

Iannone A., Giorgio F., Russo F., et al. New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study. World J Gastroenterol. 2018 Jul 21;24(27):3021-3029. doi: 10.3748/wjg.v24.i27.3021. PMID: 30038469.

Malfertheiner P., Megraud F., O’Morain C.A., et al. European Helicobacter Study Group. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084. PMID: 22491499.

Malfertheiner P., Megraud F., O’Morain C.A., et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. PMID: 27707777.

Gravina A.G., Zagari R. M., De Musis C., et al. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018 Aug 7;24(29):3204-3221. doi: 10.3748/wjg.v24.i29.3204. PMID: 30090002.

Wang J.W., Tseng K. L., Hsu C. N., et al. Association between Helicobacter pylori eradication and the risk of coronary heart diseases. PLoS One. 2018 Jan 2;13(1): e0190219. doi: 10.1371/journal.pone.0190219. PMID: 29293574.

Dore M.P., Lu H., Graham D. Y. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May;65(5):870-8. doi: 10.1136/gutjnl-2015-311019. PMID: 26848181.

Yuan Y., Ford A. C., Khan K. J., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013 Dec 11;(12): CD008337. doi: 10.1002/14651858.CD008337.pub2. PMID: 24338763.

Fallone C.A., Moss S. F., Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology. 2019 Jul;157(1):44-53. doi: 10.1053/j.gastro.2019.04.011. PMID: 30998990.

Sugano K., Tack J., Kuipers E. J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252. PMID: 26187502.

Ribaldone D.G., Fagoonee S., Astegiano M., et al. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. J Clin Med. 2019 Feb 6;8(2):199. doi: 10.3390/jcm8020199. PMID: 30736338.

Miftahussurur M., Cruz M., Doohan D., et al. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PLoS One. 2019 Mar 27;14(3): e0213868. doi: 10.1371/journal.pone.0213868. PMID: 30917150.

Miftahussurur M., Aftab H., Shrestha P. K., et al. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control. 2019 Feb 15;8:40. doi: 10.1186/s13756-019-0482-x. PMID: 30815255.

Lv Z., Wang B., Zhou X., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015 Mar;9(3):707-716. doi: 10.3892/etm.2015.2174. PMID: 25667617.

Angsantikul P., Thamphiwatana S., Zhang Q., et al. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv Ther (Weinh). 2018 Jun;1(2):1800016. doi: 10.1002/adtp.201800016. PMID: 30320205.

Shi X., Zhang J., Mo L., et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019 Apr;98(15): e15180. doi: 10.1097/MD.0000000000015180. PMID: 30985706.

Sakurai K., Suda H., Ido Y., et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol. 2017 Jan 28;23(4):668-675. doi: 10.3748/wjg.v23.i4.668. PMID: 28216974.

Ashida K., Honda Y., Sanada K., Takemura Y., Sakamoto S. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance. Expert Opin Drug Saf. 2019 Dec;18(12):1255-1261. doi: 10.1080/14740338.2019.1676722. PMID: 31646920.

Furuta T., Yamade M., Kagami T., et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. Digestion. 2020;101(6):743-751. doi: 10.1159/000502287. PMID: 31434101.

Jones N.L., Koletzko S., Goodman K., et al; Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. doi: 10.1097/MPG.0000000000001594. PMID: 28541262.

Safavi M., Sabourian R., Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases. 2016 Jan 16;4(1):5-19. doi: 10.12998/wjcc.v4.i1.5. PMID: 26798626.

Malfertheiner P., Selgrad M., Wex T., et al. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. PMID: 30042064.

Kawada M., Inoue H., Ohba S., et al. Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2. J Antibiot (Tokyo). 2013 Sep;66(9):543-8. doi: 10.1038/ja.2013.42. PMID: 23632919.

Ohishi T., Masuda T., Abe H., et al. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection. Helicobacter. 2018 Apr;23(2): e12470. doi: 10.1111/hel.12470. PMID: 29488678.

Liou J.M., Lee Y. C., El-Omar E.M., Wu M. S. Efficacy and Long-Term Safety of H. pylori Eradication for Gastric Cancer Prevention. Cancers (Basel). 2019 Apr 28;11(5):593. doi: 10.3390/cancers11050593. PMID: 31035365.

Safarov T., Kiran B., Bagirova M., Allahverdiyev A. M., Abamor E. S. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Rev Anti Infect Ther. 2019 Oct;17(10):829-840. doi: 10.1080/14787210.2019.1677464. PMID: 31591930.

Li P., Chen X., Shen Y., et al. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019 Apr 28;300:52-63. doi: 10.1016/j.jconrel.2019.02.039. PMID: 30825476.

The authors declare that there are no conflicts of interest present.